Targets › CHRM3
32 programs from 28 companies in 144 trials: 51 Phase 3, 38 Phase 4, 33 Phase 2, 22 Phase 1; Respiratory, Other, Ophthalmology; next expected readout Nov 2026.
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. (UniProt, P20309)
Open in Phaseline: the race on CHRM3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | Trospium Chloride Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Schizophrenia; Bipolar-I Disorder With Mania or Mania With Mixed Features; Bipolar Disorder Type I With Mania or Mania With Mixed Features; Mania … | Nov 2026 |
| Bristol-Myers Squibb | Trospium Chloride (BMS-986510) Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Healthy Volunteers; Psychosis Associated With Alzheimer's Disease; Alzheimer Disease; Schizophrenia | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| University of Tennessee Graduate School of Medicine | Revefenacin Muscarinic acetylcholine receptor M3 antagonist | CHRM3 | Phase 4 | COPD (Chronic Obstructive Pulmonary Disease) | Dec 2026 |
| Mackay Memorial Hospital | Solifenacin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Effect of Drug; Urinary Bladder, Overactive | Dec 2026 |
| Dr. J. Alberto Neder | Ipratropium Muscarinic acetylcholine receptor M3 antagonist | CHRM3 | Phase 4 | COPD | Jan 2027 |
| GSK | Umeclidinium Muscarinic acetylcholine receptor M3 antagonist | CHRM3 | Phase 4 | Asthma; COPD (Chronic Obstructive Pulmonary Disease); Chronic Obstructive Pulmonary Disease (COPD) | Jun 2027 |
| Mansoura University | Solifenacin succinate Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Overactive Bladder (OAB); Nocturnal Enuresis in Children | Jun 2027 |
| University of Aarhus | Solifenacin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 4 | Urinary Incontinence in Children | Oct 2027 |
| AstraZeneca | Breztri Aerosphere Triple combination: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonis | ADRB2, CHRM3 | Phase 4 | Moderate to Severe COPD | Dec 2027 |
| Sairam Parthasarathy | Atomoxetine-oxybutynin Norepinephrine reuptake inhibitor combined with muscarinic-3 receptor antagonist to increa | SLC6A2, CHRM3 | Phase 4 | Obstructive Sleep Apnea (OSA) | Mar 2030 |
| Southern College of Optometry | Pilocarpine Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM3, CHRM1 | Phase 4 | Presbyopia | – |
| University of California, Davis | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Overactive Bladder Syndrome | Dec 2026 |
| Bir Hospital | Solifenacin Succinate Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Ureteral Stent-Related Symptom | Dec 2026 |
| GSK | FF/UMEC/VI Inhaled corticosteroid/muscarinic antagonist/long-acting beta-2 agonist combination | CHRM3, ADRB2 | Phase 3 | Asthma | Jan 2027 |
| AstraZeneca | BGF MDI 320/14.4/9.6 μg Triple therapy: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonist (g | ADRB2, CHRM3 | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) | Dec 2027 |
| Ocus Innovation Ireland | Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia | Dec 2027 |
| Oslo University Hospital | Buscopan 20 MG/ML Injectable Solution Anticholinergic agent that reduces smooth muscle spasms | CHRM1, CHRM3 | Phase 3 | Labor Complication | Dec 2027 |
| Central Hospital, Nancy, France | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Spina Bifida | Jan 2028 |
| Montefiore Medical Center | Pilocarpine Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M1 agonist | CHRM3, CHRM1 | Phase 3 | Glaucoma | Jun 2028 |
| Chiesi Farmaceutici | CHF 5993 100/6/12.5 μg pMDI HFA-152a Triple combination of inhaled corticosteroid, long-acting beta-2 agonist, and long-acting | ADRB2, CHRM3 | Phase 3 | Asthma | Oct 2028 |
| Sherief Abd-Elsalam | orphenadrine Anticholinergic drug with CNS and peripheral activity; used for muscle spasms and pain | CHRM1, CHRM2, CHRM3 | Phase 3 | Liver Cirrhosis | Dec 2028 |
| Reinier de Graaf Groep | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 3 | Breast Cancer | Jan 2029 |
| Zhaoke (Guangzhou) Ophthalmology Pharmaceutical | Atropine Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 3 | Myopia; Achalasia; Progressive Myopia; Focus on Axial Length … | – |
| Belfast Health and Social Care Trust | Atropine Sulfate Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM1, CHRM2 | Phase 2 | Myopia | Feb 2027 |
| Novartis | Glycopyrronium bromide Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist | CHRM3, CHRM1 | Phase 2 | Asthma; Post-Dural Puncture Headache | Jul 2027 |
| Oliver Blanchard | Darifenacin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 2 | Amyotrophic Lateral Sclerosis | Oct 2027 |
| University of Virginia | Anoro Ellipta Long-acting muscarinic antagonist (umeclidinium) + long-acting beta-2 agonist (vilanterol) | CHRM3, ADRB2 | Phase 2 | Chronic Obstructive Pulmonary Disease | Jan 2028 |
| University Hospital, Bordeaux | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 2 | Male Urogenital Diseases | Feb 2028 |
| AstraZeneca | Glycopyrronium Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor | CHRM3, CHRM1, CHRM4, CHRM2, CHRM5 | Phase 2 | Asthma | May 2029 |
| University of Arizona | Oxybutynin Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist | CHRM3, CHRM2 | Phase 2 | Obstructive Sleep Apnea | – |
| University Hospital, Lille | TRIXEO AEROSPHERE (BGF 160) Fixed triple combination: long-acting beta-2 agonist (formoterol), long-acting muscarinic | ADRB2, CHRM3, NR3C1 | Phase 1 | Copd | – |
Myopia (17) Asthma (7) Schizophrenia (6) Alzheimer Disease (4) Healthy Volunteers (4) Alzheimer's Disease (3) Psychosis Associated With Alzheimer's Disease (3) COPD (Chronic Obstructive Pulmonary Disease) (3) Nicotine Dependence (3) Progressive Myopia (2) Myopia, Progressive (2) Urinary Incontinence in Children (2)
small molecule (30), protein or peptide (1)
AstraZeneca (3) Bristol-Myers Squibb (2) GSK (2) Zhaoke (Guangzhou) Ophthalmology Pharmaceutical (1) University of Arizona (1) Bir Hospital (1) University of Aarhus (1) University of Virginia (1) Reinier de Graaf Groep (1) Montefiore Medical Center (1) Ocus Innovation Ireland (1) University Hospital, Bordeaux (1) University of California, San Francisco (1) Belfast Health and Social Care Trust (1) Oslo University Hospital (1) Mackay Memorial Hospital (1) Chiesi Farmaceutici (1) Dr. J. Alberto Neder (1) Sairam Parthasarathy (1) Central Hospital, Nancy, France (1)
CHRM2 (18) CHRM1 (9) ADRB2 (7) NR3C1 (2) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1) MS4A1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.